Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo

Tel:  +47 21 07 81 60

Alterations in ATC/DDD

Overview of ATC/DDD alterations decided at the two previous meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC/DDD alterations from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the alterations will be considered final and included in the ATC/DDD index. The year of implementation in the ATC/DDD index is given in the list. 

Please note that all ATC and DDD alterations are valid and implemented annually.

Change of DDDs

ATC codeLevel namePrevious DDDNew DDDDeadline for objection to temporary alterations Implementation in ATC/DDD index
L04AC01daclizumab0.35 g 1) P5 mg P01.02.20172018
1) course dose

Change of ATC level name

Previous nameNew ATC level nameATC codeDeadline for objection to temporary alterations Implementation in ATC/DDD index
amoxicillin and enzyme inhibitoramoxicillin and beta-lactamase inhibitorJ01CR0201.02.20172018
ampicillin and enzyme inhibitorampicillin and beta-lactamase inhibitorJ01CR0101.02.20172018
Bile acid preparationsBile acids and derivativesA05AA01.02.20172018
cefoperazone, combinationscefoperazone and beta-lactamase inhibitorJ01DD6201.02.20172018
cefotaxime, combinationscefotaxime and beta-lactamase inhibitorJ01DD5101.02.20172018
ceftazidime, combinationsceftazidime and beta-lactamase inhibitorJ01DD5201.02.20172018
ceftolozane and enzyme inhibitorceftolozane and beta-lactamase inhibitorJ01DI5401.02.20172018
imipenem and enzyme inhibitorimipenem and cilastatinJ01DH5101.02.20172018
piperacillin and enzyme inhibitorpiperacillin and beta-lactamase inhibitorJ01CR0501.02.20172018
ticarcillin and enzyme inhibitorticarcillin and beta-lactamase inhibitorJ01CR0301.02.20172018

Change in ATC codes

INN/generic namePrevious ATC codeNew ATC codeDeadline for objection to temporary alterations Implementation in ATC/DDD index
argipressinH01BA06H01BA01 1)01.02.20172018
benzydamine A01AD02R02AX03 2)01.02.20172018
ceftriaxone, combinationsJ01DD54J01DD63 3)01.02.20172018
dasabuvir, ombitasvir, paritaprevir and ritonavirJ05AX66J05AP5201.02.20172018
elbasvir and grazoprevirJ05AX68J05AP5401.02.20172018
ombitasvir, paritaprevir and ritonavirJ05AX67J05AP5301.02.20172018
simeprevir J05AE14J05AP0501.02.20172018
sofosbuvir and ledipasvirJ05AX65J05AP5101.02.20172018
sofosbuvir and velpatasvirJ05AX69 4)J05AP5501.02.20172018
1) Altered ATC level name to vasopressin (argipressin)
2) Split of code. Alteration of ATC code includes only benzydamine lozenges
3) Split of code. Combinations of ceftriaxone and other substances remain in J01DD54 while combinations of ceftriaxone and beta-lactamase inhibitors are moved to J01DD63
4) Temporary new code in J05AX69 will be changed to J05AP55 in connection with the implementation of the proposed new ATC 4th level Antivirals for treatment of HCV infections in 2018 (see temporary list –“New ATC level codes (other than 5th levels)”

Last updated: 2016-12-06